Free Trial
→ I'm giving you a space stock today. Free. (From Behind the Markets) (Ad)tc pixel
NASDAQ:CDNA

CareDx Q3 2026 Earnings Date & Estimates

CareDx logo
$64.00 -2.68 (-4.02%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$63.62 -0.38 (-0.59%)
As of 10/16/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CareDx is scheduled to report Q3 2026 earnings on Thursday, October 29, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from CareDx in Q3 2026

CareDx is expected to post earnings of $0.2552 per share on revenue of $121.95 million. In the same quarter a year earlier CareDx reported $0.28 per share on revenue of $100.06 million. CareDx last reported on July 30, 2026, posting $0.37 per share and beating the $0.2321 consensus estimate. CareDx has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.2552
Expected Revenue
$121.95 million
Prior-Year EPS
$0.28
Prior-Year Revenue
$100.06 million
Expected EPS Growth
-8.9%
Expected Revenue Growth
+21.9%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.37 (Beat by +$0.1379)
Last Quarter Revenue
$131.95 million
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

CareDx Q3 2026 Earnings FAQ

CareDx (NASDAQ:CDNA) has confirmed it will report Q3 2026 earnings on Thursday, October 29, 2026, after market closes.

CareDx's Q3 2026 earnings conference call is scheduled for Thursday, October 29, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect CareDx to post earnings of $0.2552 per share for Q3 2026.

The consensus revenue estimate for CareDx is $121.95 million for Q3 2026.

CareDx Earnings Headlines

CareDx, Inc. (CDNA) - What Are Researchers Thinking About This Stock?
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31129828
Entrada Therapeutics (NASDAQ:TRDA) vs. CareDx (NASDAQ:CDNA) Financial Comparison
October 17 at 3:45 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31128336
The Iran War Isn’t Chaos. It’s Strategy.
Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congressmen no cameras, no staff. What he found afterward points to a coordinated Two-Front Economic War already in motion, according to his research at Behind the Markets.tc pixel
October 18 at 1:00 AM  |  Behind the Markets (Ad)
CareDx Inc (CDNA) Shares Fall 4.0% -- GF Value Says Still Overvalued
October 16 at 12:00 AM  |  gurufocus.comhttps://www.gurufocus.com/news/9128631/caredx-inc-cdna-shares-fall-40-gf-value-says-still-overvalued
CareDx to Report Third Quarter 2026 Financial Results on October 29, 2026
October 15 at 4:01 PM  |  businesswire.comhttps://www.businesswire.com/news/home/20261015254708/en/caredx-to-report-third-quarter-2026-financial-results-on-october-29-2026/
CareDx (CDNA) Stock Gets Fair Value Bump After Reimbursement And Analyst Target Changes
October 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/caredx-cdna-stock-gets-fair-002026721.html
See More CareDx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CareDx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CareDx and other key companies, straight to your email.

About CareDx

CareDx (NASDAQ:CDNA) (NASDAQ: CDNA) is a precision-medicine company focused on improving the care of organ-transplant patients. The company develops diagnostic tests, digital tools and services designed to help clinicians monitor transplant recipients, assess the risk of rejection and support long-term graft management.

CareDx’s product portfolio includes AlloMap, a gene-expression blood test used in heart-transplant surveillance, and AlloSure, a donor-derived cell-free DNA test designed to help detect potential organ injury or rejection. The company also offers HeartCare, which combines AlloMap and AlloSure for heart-transplant monitoring, as well as transplant-focused testing and care-management solutions for kidney and other transplant populations.

CareDx has its roots in the development of molecular diagnostics for transplant medicine and serves transplant centers, physicians and patients primarily in the United States, with select products and services available in international markets. Its offerings are intended to complement clinical evaluation and help reduce reliance on more invasive monitoring procedures.

View CareDx Profile
Earnings Tools